<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228318</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00038739</org_study_id>
    <secondary_id>BLIR-HIV</secondary_id>
    <nct_id>NCT01228318</nct_id>
  </id_info>
  <brief_title>Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)</brief_title>
  <acronym>BLIR-HIV</acronym>
  <official_title>Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to
      be compounded by HIV/AIDS and HAART-associated bone loss. Mechanistically, osteoclasts the
      cells responsible for bone resorption form under the influence of the key osteoclastogenic
      cytokine receptor activator of nuclear factor kappa-Β ligand (RANKL). The osteoclastogenic
      and proresorptive activities of RANKL are moderated by its physiological decoy receptor
      osteoprotegerin (OPG). Imbalance in the ratio of RANKL to OPG alters osteoclastic bone
      resorption and lead to osteoporosis. Activated T- and B-cells are a major source of RANKL,
      while normal physiological B-cells are a major source of OPG. T-cells regulate the production
      of OPG by B-cells. Thus changes in the immune system induced by HIV/AIDS and/or by HAART
      could affect B-cell and T-cells RANKL and OPG production. Indeed, data from our group shows
      that in an animal model of HIV/AIDS, the HIV-1 Transgenic rat, the development of
      osteoporosis is recapitulated as observed in HIV-infected patients, and B-cell OPG and RANKL
      production are concurrently down regulated and upregulated respectively. Furthermore,
      preliminary data in HIV-infected subjects suggests dramatic acute upswing in bone resorption
      following HAART initiation that peaks at 12 weeks and then declines. Based on these findings,
      the investigators hypothesize HAART associated bone loss is driven by immune reconstitution.
      Because this effect of HAART is dramatic in magnitude but short in duration, the
      investigators propose to apply antiresorptive agent (zoledronic acid, reclast®) to
      specifically spare patients from this dramatic but acute bone damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a prospective, blinded placebo-controlled randomized trial, treatment naïve HIV-infected
      subjects initiating HAART will be assigned to HAART + zoledronic acid or HAART + placebo.
      Serial assessment of serum levels of bone markers, cellular expression of OPG/RANKL and other
      cytokines, cellular immune activation markers, serum bone regulating hormones, and bone
      mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) scan will be undertaken at
      pre-defined time points from baseline through week 144 of HAART.

      In the primary analysis, changes in serum C-Terminal Telopeptide (CTx) level, BMD, and
      cellular OPG/RANKL expression from baseline through week 24 will be quantitated and
      subsequently compared between treatment arms. In addition, the impact of zoledronic acid
      administration on these covariates will be assessed at various study time points. The
      relationship between OPG/RANKL expression, immune activation, serum bone regulating hormonal
      levels, and bone turnover will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 13, 2017</completion_date>
  <primary_completion_date type="Actual">April 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels</measure>
    <time_frame>Baseline, Week 12 through Week 144</time_frame>
    <description>Serum C-terminal telopeptide of collagen (CTx) levels through week 144 were examined by evaluating the baseline-adjusted means. The baseline-adjusted CTx mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at each scheduled clinical visit. The expected outcome is that HIV-infected individuals will display increased indices of bone resorption (CTx) as a result of diminished bone mineral density (BMD). Lower CTx values indicate that better maintenance of bone mineral density.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline-Adjusted Means of Osteocalcin</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>Osteocalcin was evaluated to examine the inhibitory effect of single dose zoledronic acid on HAART associated changes in markers of bone turnover. Osteocalcin is released from bone during resorption and higher levels in the circulatory system indicate increased bone turnover. HIV-infected individuals are expected to have increased bone resorption. The baseline-adjusted osteocalcin mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at the Week 144 clinic visit. Baseline-adjusted means of osteocalcin at week 144 are presented.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline-Adjusted Means of Dual-energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>Development of osteoporosis was assessed by examining bone mineral density (BMD) by DXA scan. Baseline-adjusted means of DXA scan Z-scores are presented for the lumbar spine (L1-L4), left hip, and femur neck. The baseline-adjusted BMD mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at the Week 144 clinic visit. Bone density Z-scores tell how close to the average that a person is (adjusted for age, race, and gender). A Z-score of 0 means the value matches that of the average person. Z-score values below 0 indicate lower than average bone density while values above 0 indicate higher bone density than the average person.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>HIV Infection</condition>
  <condition>Bone Loss</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <other_name>Reclast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infection, as documented by any licensed serologic test and confirmed by a
             western blot or by a positive plasma HIV-1 RNA performed by any laboratory that has a
             Clinical Laboratory Improvement Amendments (CLIA) certification.

          2. Meets Grady Infectious Disease Program (IDP) clinical criteria for antiretroviral
             therapy initiation, and subject and his/her provider are agreeable to subject
             initiating therapy with a regimen consisting of atazanavir (ATV)/ritonavir (RTV) +
             emtricitabine (FTC)/tenofovir (TDF) as part of his/her routine HIV management.

          3. Ambulatory men and women age ≥ 30 ≤ 50 years.

          4. Ability and willingness of subject or legal guardian/representative to give written
             informed consent.

          5. Antiretroviral (ARV) drug-naïve (defined as ≤ 10 days of antiretroviral therapy (ART)
             at any time prior to entry).

          6. Screening HIV-1 RNA ≥ 1000 copies/mL obtained within 90 days prior to study entry by
             any FDA-approved test for quantifying HIV-1 RNA at any laboratory that has a CLIA
             certification.

          7. Laboratory values obtained within 90 days prior to study entry.

               -  Absolute neutrophil count (ANC) ≥ 500/mm3

               -  Hemoglobin ≥ 8.0 g/dL

               -  Platelet count ≥ 40,000/mm3

               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
                  phosphatase ≥ 3 x upper limit of normal (ULN)

               -  Total bilirubin ≥ 2.5 x ULN

               -  Calcium ≥ 8.0 mg/dL

               -  Serum vitamin D level ≥ 12ng/mL

               -  Creatinine clearance (CrCl) ≥ 50 mL/min as estimated by the Cockcroft-Gault
                  equation.

          8. Absence of history of non-HIV related active immunological or bone disorders such as:

               -  Bone marrow or organ transplantation

               -  Inflammatory bowel disease (ulcerative colitis, Crohn's disease)

               -  Multiple Myeloma

               -  Osteogenesis imperfecta

               -  Osteomalacia

               -  Osteosarcoma

               -  Paget's disease

               -  Postmenopausal osteoporosis

               -  Rheumatoid arthritis

               -  Systemic lupus erythematosus

               -  Thyroid disorders (hyper/hypothyroidism)

          9. Contraception requirements

               1. Female Subjects of Reproductive Potential:

                  Female subjects of reproductive potential, who are participating in sexual
                  activity that could lead to pregnancy, must agree to use at least one reliable
                  method of contraception while participating in the study. Acceptable methods of
                  contraception include:

                    -  Condoms (male or female) with or without a spermicidal agent

                    -  Diaphragm or cervical cap with spermicide

                    -  Intrauterine device (IUD)

                    -  Hormone-based contraceptive (must contain at ≥ 35 mcg of ethinyl estradiol)

               2. Female Subjects Who Are Not of Reproductive Potential.

        Exclusion Criteria:

          1. Pregnancy or breast feeding

          2. Physical or biochemical evidence or a medical history of malignancy.

          3. Currently (within the past 8 weeks) taking any medication with known influence on the
             immune or skeletal system (e.g. immune modulation therapy, glucocorticoids, steroid
             hormones, other bisphosphonates).

          4. Osteoporosis defined as T-score &lt;-2.5 at the hip, or spine, or history of osteoporotic
             fracture.

          5. Prior or current use of zoledronic acid (reclast®)

          6. Recent (within the past 6 months) or planned (within the next 6 months) invasive
             dental procedure.

          7. Known allergy/sensitivity to study drugs or their formulations or mammalian cell
             derived drug products.

          8. Any condition that, in the opinion of the investigators, would compromise the
             subject's ability to participate in the study.

          9. Serious illness requiring systemic treatment and/or hospitalization until subject
             either completes therapy or is clinically stable on therapy, in the opinion of the
             investigators, for at least 7 days prior to study entry.

         10. Requirement for any current medications that are prohibited with any study drugs.
             Prohibited medications must be discontinued at least 30 days prior to entry.

         11. Current imprisonment or involuntary incarceration in a medical facility for
             psychiatric or physical illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igho Ofotokun, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mervyn N Weitzmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Infectious Diseases Clinic (Ponce Center)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, Ofotokun I, Weitzmann MN. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13848-53. doi: 10.1073/pnas.1003020107. Epub 2010 Jul 19.</citation>
    <PMID>20643942</PMID>
  </reference>
  <reference>
    <citation>Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010 Dec;17(6):523-9. doi: 10.1097/MED.0b013e32833f48d6. Review.</citation>
    <PMID>20844427</PMID>
  </reference>
  <results_reference>
    <citation>Ofotokun I, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford SE, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley KA, Powers P, Weitzmann MN. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clin Infect Dis. 2016 Sep 1;63(5):663-671. doi: 10.1093/cid/ciw331. Epub 2016 May 18.</citation>
    <PMID>27193748</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 23, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <results_first_submitted>March 27, 2018</results_first_submitted>
  <results_first_submitted_qc>June 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2018</results_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Ighovwerha Ofotokun</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HAART</keyword>
  <keyword>Antiresorptive drugs</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>Bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT01228318/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT01228318/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At the Grady Hospital Infectious Disease Clinic 343 subjects were assessed for eligibility and 280 were excluded. 63 viremic treatment-naïve adult HIV-infected subjects were randomized in a double-blinded, placebo-controlled study (ART+placebo N=29; ART+Zoledronic acid N=34). Participants were enrolled between January 2011 and August 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid</title>
          <description>Participants in this arm received a 5 milligrams (mg)/100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Study visits occurred at 12, 24, 48, 96, and 144 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants in the placebo arm received a placebo to match the study drug, containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered intravenously over 15-30 minutes under the supervision of study personnel.
Study visits occurred at 12, 24, 48, 96, and 144 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Clinic no show to receive intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to contact</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid</title>
          <description>Participants in this arm received a 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants in the placebo arm received a placebo to match the study drug, containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered intravenously over 15-30 minutes under the supervision of study personnel.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.4" lower_limit="18.9" upper_limit="41.2"/>
                    <measurement group_id="B2" value="23.8" lower_limit="16.9" upper_limit="38.7"/>
                    <measurement group_id="B3" value="23.8" lower_limit="16.9" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster of differentiation 4 (CD4) T-cell count</title>
          <units>cells/uL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.5" lower_limit="5" upper_limit="239"/>
                    <measurement group_id="B2" value="117" lower_limit="3" upper_limit="574"/>
                    <measurement group_id="B3" value="101" lower_limit="3" upper_limit="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 Viral Load</title>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.97" lower_limit="3.69" upper_limit="6.44"/>
                    <measurement group_id="B2" value="4.93" lower_limit="2.51" upper_limit="6.06"/>
                    <measurement group_id="B3" value="4.96" lower_limit="2.51" upper_limit="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.9" lower_limit="49.8" upper_limit="118.2"/>
                    <measurement group_id="B2" value="73.3" lower_limit="54.9" upper_limit="107.2"/>
                    <measurement group_id="B3" value="73.3" lower_limit="49.8" upper_limit="118.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="30" upper_limit="50"/>
                    <measurement group_id="B2" value="37" lower_limit="30" upper_limit="51"/>
                    <measurement group_id="B3" value="38" lower_limit="30" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="61" upper_limit="76"/>
                    <measurement group_id="B2" value="70" lower_limit="61" upper_limit="77"/>
                    <measurement group_id="B3" value="70" lower_limit="61" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels</title>
        <description>Serum C-terminal telopeptide of collagen (CTx) levels through week 144 were examined by evaluating the baseline-adjusted means. The baseline-adjusted CTx mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at each scheduled clinical visit. The expected outcome is that HIV-infected individuals will display increased indices of bone resorption (CTx) as a result of diminished bone mineral density (BMD). Lower CTx values indicate that better maintenance of bone mineral density.</description>
        <time_frame>Baseline, Week 12 through Week 144</time_frame>
        <population>Participants with CTx measurements at the indicated week are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels</title>
          <description>Serum C-terminal telopeptide of collagen (CTx) levels through week 144 were examined by evaluating the baseline-adjusted means. The baseline-adjusted CTx mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at each scheduled clinical visit. The expected outcome is that HIV-infected individuals will display increased indices of bone resorption (CTx) as a result of diminished bone mineral density (BMD). Lower CTx values indicate that better maintenance of bone mineral density.</description>
          <population>Participants with CTx measurements at the indicated week are included in this analysis.</population>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.092" lower_limit="0.040" upper_limit="0.145"/>
                    <measurement group_id="O2" value="0.297" lower_limit="0.240" upper_limit="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" lower_limit="0.074" upper_limit="0.171"/>
                    <measurement group_id="O2" value="0.331" lower_limit="0.276" upper_limit="0.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" lower_limit="0.077" upper_limit="0.168"/>
                    <measurement group_id="O2" value="0.264" lower_limit="0.215" upper_limit="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.138" lower_limit="0.088" upper_limit="0.189"/>
                    <measurement group_id="O2" value="0.242" lower_limit="0.188" upper_limit="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.126" lower_limit="0.042" upper_limit="0.209"/>
                    <measurement group_id="O2" value="0.321" lower_limit="0.238" upper_limit="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137" lower_limit="0.088" upper_limit="0.187"/>
                    <measurement group_id="O2" value="0.201" lower_limit="0.151" upper_limit="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.148" lower_limit="0.096" upper_limit="0.200"/>
                    <measurement group_id="O2" value="0.200" lower_limit="0.147" upper_limit="0.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-Adjusted Means of Osteocalcin</title>
        <description>Osteocalcin was evaluated to examine the inhibitory effect of single dose zoledronic acid on HAART associated changes in markers of bone turnover. Osteocalcin is released from bone during resorption and higher levels in the circulatory system indicate increased bone turnover. HIV-infected individuals are expected to have increased bone resorption. The baseline-adjusted osteocalcin mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at the Week 144 clinic visit. Baseline-adjusted means of osteocalcin at week 144 are presented.</description>
        <time_frame>Baseline, Week 144</time_frame>
        <population>Participants with osteocalcin measurements at Week 144 are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-Adjusted Means of Osteocalcin</title>
          <description>Osteocalcin was evaluated to examine the inhibitory effect of single dose zoledronic acid on HAART associated changes in markers of bone turnover. Osteocalcin is released from bone during resorption and higher levels in the circulatory system indicate increased bone turnover. HIV-infected individuals are expected to have increased bone resorption. The baseline-adjusted osteocalcin mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at the Week 144 clinic visit. Baseline-adjusted means of osteocalcin at week 144 are presented.</description>
          <population>Participants with osteocalcin measurements at Week 144 are included in this analysis.</population>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.176" lower_limit="4.557" upper_limit="13.796"/>
                    <measurement group_id="O2" value="13.597" lower_limit="8.862" upper_limit="18.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Baseline-Adjusted Means of Dual-energy X-ray Absorptiometry (DXA)</title>
        <description>Development of osteoporosis was assessed by examining bone mineral density (BMD) by DXA scan. Baseline-adjusted means of DXA scan Z-scores are presented for the lumbar spine (L1-L4), left hip, and femur neck. The baseline-adjusted BMD mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at the Week 144 clinic visit. Bone density Z-scores tell how close to the average that a person is (adjusted for age, race, and gender). A Z-score of 0 means the value matches that of the average person. Z-score values below 0 indicate lower than average bone density while values above 0 indicate higher bone density than the average person.</description>
        <time_frame>Baseline, Week 144</time_frame>
        <population>This analysis includes participants who had a DXA scan performed at baseline and at least one additional study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-Adjusted Means of Dual-energy X-ray Absorptiometry (DXA)</title>
          <description>Development of osteoporosis was assessed by examining bone mineral density (BMD) by DXA scan. Baseline-adjusted means of DXA scan Z-scores are presented for the lumbar spine (L1-L4), left hip, and femur neck. The baseline-adjusted BMD mean is defined as the predicted response value obtained by fitting the regression equation for each treatment arm at the mean baseline value for the 2 treatment arms. The adjusted means were estimated using analysis of covariance at the Week 144 clinic visit. Bone density Z-scores tell how close to the average that a person is (adjusted for age, race, and gender). A Z-score of 0 means the value matches that of the average person. Z-score values below 0 indicate lower than average bone density while values above 0 indicate higher bone density than the average person.</description>
          <population>This analysis includes participants who had a DXA scan performed at baseline and at least one additional study visit.</population>
          <units>Z score</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.177" lower_limit="-0.371" upper_limit="0.016"/>
                    <measurement group_id="O2" value="-0.836" lower_limit="-1.062" upper_limit="-0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.860" lower_limit="-0.992" upper_limit="-0.728"/>
                    <measurement group_id="O2" value="-1.092" lower_limit="-1.246" upper_limit="-0.938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.665" lower_limit="-0.833" upper_limit="-0.498"/>
                    <measurement group_id="O2" value="-0.817" lower_limit="-1.012" upper_limit="-0.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Participants With Virological Suppression by Week 144</title>
        <description>The percentage of participants achieving viral load suppression by study week 144. Virologic suppression was defined as HIV RNA polymerase chain reaction (PCR) (viral loads) less than 50 copies per mL.</description>
        <time_frame>Week 144</time_frame>
        <population>All participants are included in this analysis, using all available measurements of viral load.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virological Suppression by Week 144</title>
          <description>The percentage of participants achieving viral load suppression by study week 144. Virologic suppression was defined as HIV RNA polymerase chain reaction (PCR) (viral loads) less than 50 copies per mL.</description>
          <population>All participants are included in this analysis, using all available measurements of viral load.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>CD4 T Cell Count</title>
        <description>Immunologic response measured by CD4 T cell count by treatment arm and weeks on study.</description>
        <time_frame>Baseline, Week 144</time_frame>
        <population>This analysis includes participants with a CD4 count measurement at the time points indicated.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>Subjects in this arm will receive 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
Zoledronic acid: a. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
b. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 T Cell Count</title>
          <description>Immunologic response measured by CD4 T cell count by treatment arm and weeks on study.</description>
          <population>This analysis includes participants with a CD4 count measurement at the time points indicated.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="69"/>
                    <measurement group_id="O2" value="155" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347" spread="27"/>
                    <measurement group_id="O2" value="439" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse effects elicited from the BLIR patient at each scheduled visit (12, 24, 48, 96, and 144 weeks) using the Case Report Form Checklist of 36 HAART Signs and Symptoms. Participants were also volunteered complaints of side effects that were outside of the checklist.</time_frame>
      <desc>The definition of adverse event and/or serious adverse event, used to collect adverse event information, does not differ from the ClinicalTrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid</title>
          <description>Participants in this arm received a 5mg/100mL solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants in the placebo arm received a placebo to match the study drug, containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered intravenously over 15-30 minutes under the supervision of study personnel.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hospitalization related to Graves' Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to gastro esphageal reflux disease</sub_title>
                <description>Participant was admitted due to chest pain and abnormal electrocardiogram; cardiac tests were normal and gastro esophageal reflux disease was diagnosed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to abdominal pain</sub_title>
                <description>Participant was hospitalized with complaints of abdominal pain and was discharged after being observed for 24 hours.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Participant was admitted with multiple diagnoses that were unrelated to study treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to neurosyphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric hospitalization</sub_title>
                <description>Participant admitted to psychiatric unit due to homicidal intentions against family member. This event is considered unrelated to study treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to community acquired pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hospitalization due to brochitis and otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to sub-acute cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="15" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain in right ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Decreased hearing/ear stopped up</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Itchy/watery eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Seeing spots</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="113" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E2" events="69" subjects_affected="18" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="128" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E2" events="91" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="42" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E2" events="34" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="20" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="29" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" events="25" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bloody stool</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bitter mouth taste</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="176" subjects_affected="28" subjects_at_risk="34"/>
                <counts group_id="E2" events="145" subjects_affected="22" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="87" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E2" events="56" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="110" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E2" events="81" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Numbness/tingling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="156" subjects_affected="27" subjects_at_risk="34"/>
                <counts group_id="E2" events="114" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Decreased libido</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="127" subjects_affected="24" subjects_at_risk="34"/>
                <counts group_id="E2" events="92" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="46" subjects_affected="21" subjects_at_risk="34"/>
                <counts group_id="E2" events="42" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="66" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E2" events="63" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="140" subjects_affected="21" subjects_at_risk="34"/>
                <counts group_id="E2" events="90" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Myalgias</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="99" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E2" events="89" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Arthralgias</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="71" subjects_affected="18" subjects_at_risk="34"/>
                <counts group_id="E2" events="105" subjects_affected="17" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flulike symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="34"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="29" subjects_affected="17" subjects_at_risk="34"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="55" subjects_affected="17" subjects_at_risk="34"/>
                <counts group_id="E2" events="45" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="76" subjects_affected="17" subjects_at_risk="34"/>
                <counts group_id="E2" events="93" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Loss of memory</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="99" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E2" events="83" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="36" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E2" events="45" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Motor weakness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="32" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E2" events="78" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="33" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="62" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" events="20" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="37" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="28" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="30" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="12" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" events="19" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tooth ache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="42" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Generalized muscle pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="9" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Left eye twitching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Intermittent nose bleed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Throat pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bruising easily</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bump inside mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Easily distracted</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Entire body heat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>General body aches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hair thinning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hotflashes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Left sided weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Numbness (hands, legs, body)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Loss of balance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Right facial swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Right side weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="9" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Salivation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Stomach feels tight</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral thrush</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" events="14" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain from shingles</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Boil left buttock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Herpes outbreak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps (hands, feet, legs)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Foot pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ankle tenderness/pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Arm pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bone pain in left hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Knee swollen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lower left leg pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neck pain/stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="11" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain in right knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Right shoulder discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Right wrist pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Kaposi sarcoma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="150" subjects_affected="21" subjects_at_risk="34"/>
                <counts group_id="E2" events="131" subjects_affected="16" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hearing voices</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dark urine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vaginal itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="141" subjects_affected="28" subjects_at_risk="34"/>
                <counts group_id="E2" events="79" subjects_affected="22" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nasal/sinus drainage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="141" subjects_affected="28" subjects_at_risk="34"/>
                <counts group_id="E2" events="79" subjects_affected="22" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="101" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E2" events="94" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Burning in chest with excertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash (head, shoulder, feet)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="90" subjects_affected="21" subjects_at_risk="34"/>
                <counts group_id="E2" events="76" subjects_affected="18" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dark spots</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Facial acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash left forehead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Scalp pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Welts when skin scratched</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vein distended</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="15" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="17" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This single site proof-of-concept phase 2b study had a small sample size &amp; a 144-week study duration so it could not evaluate the impact of the intervention on long-term bone outcomes. The population enrolled limited the generalization of findings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Igho Ofotokun, MD, MSc</name_or_title>
      <organization>Emory University</organization>
      <phone>404-616-0659</phone>
      <email>iofotok@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

